| Bioactivity | BACE1-IN-13 (Compound 36) is an orally active BACE1 inhibitor with an IC50 value of 2.9 nM. BACE1-IN-13 is highly potent in hAβ42 cell (IC50 = 1.3 nM). BACE1-IN-13 has cardiovascularly safty and elicits sustained Aβ42 reduction in mouse and dog animal models[1]. |
| Target | IC50: 1.3 nM (hAβ42 cell). |
| Name | BACE1-IN-13 |
| CAS | 1397683-26-9 |
| Formula | C20H17FN8O2 |
| Molar Mass | 420.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Peschiulli A, et al. A Brain-Penetrant and Bioavailable Pyrazolopiperazine BACE1 Inhibitor Elicits Sustained Reduction of Amyloid β In Vivo. ACS Med Chem Lett. 2021 Dec 1;13(1):76-83. |
BACE1-IN-13
CAS: 1397683-26-9 F: C20H17FN8O2 W: 420.40
BACE1-IN-13 (Compound 36) is an orally active BACE1 inhibitor with an IC50 value of 2.9 nM. BACE1-IN-13 is highly potent
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.